Sensyne Health signs research collaboration deal with Bristol Myers Squibb

Clinical artificial intelligence (AI) company Sensyne Health has signed a research collaboration agreement with Bristol Myers Squibb, it announced on Friday.

The AIM-traded firm said that initially, the collaboration would focus on applying its proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases, within the broader group of myeloproliferative neoplasms.

It said myeloproliferative neoplasms comprise a group of rare blood diseases, characterised by the overproduction of one or more types of blood cells, being red blood cells, white blood cells and platelets.

The collaboration would be Sensyne’s fourth successive partnership with a major pharmaceutical company, following collaborations signed with Bayer, Roche and Alexion.

No financial terms were disclosed.

“This new collaboration with one of the world's leading pharmaceutical companies is a further validation of Sensyne's unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the ethical commercialisation of such data,” said chief executive officer Lord Drayson.

“As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”

At 1135 BST, shares in Sensyne Health were up 7.95% at 99.85p.